[ Inside the business ]

ZTS stock analysis

ZTS · Zoetis Inc.

Pharmaceutical preparations. Shrinking 1%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Largest Customer: 16%
Largest Customer 16%Everyone else
Prepaid $18MSales −1%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 70% → 72%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.0%/yrDebt $9B
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +3%, −0%, then −1% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2022 rate shock it fell 39% while the market fell 24%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: debt over 4× operating profit.

What they sell

24% Parasiticides.

Parasiticides 24% · Cattle 18% · Dermatology 17% · Anti-infective Products 12% · other (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 109¢ of each $1 of profit.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

8% on research.

$722M a year on R&D. $493M on equipment and buildings.

All figures from Zoetis Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.